<?xml version="1.0" encoding="UTF-8"?>
<ref id="pntd.0007860.ref026">
 <label>26</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Priddy</surname>
   <given-names>FH</given-names>
  </name>, 
  <name>
   <surname>Lewis</surname>
   <given-names>DJM</given-names>
  </name>, 
  <name>
   <surname>Gelderblom</surname>
   <given-names>HC</given-names>
  </name>, 
  <name>
   <surname>Hassanin</surname>
   <given-names>H</given-names>
  </name>, 
  <name>
   <surname>Streatfield</surname>
   <given-names>C</given-names>
  </name>, 
  <name>
   <surname>LaBranche</surname>
   <given-names>C</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial</article-title>. 
  <source>Lancet HIV</source>. 
  <year>2019</year>;
  <volume>6</volume>(
  <issue>4</issue>):
  <fpage>e230</fpage>â€“
  <lpage>e9</lpage>. 
  <pub-id pub-id-type="doi">10.1016/S2352-3018(19)30003-7</pub-id>
  <?supplied-pmid 30885692?>
  <pub-id pub-id-type="pmid">30885692</pub-id>
 </mixed-citation>
</ref>
